Successful treatment of secukinumab in a ten-year old with generalized pustular psoriasis recalcitrant with conventional therapy

Authors

  • Windy Keumala Budianti
  • Arlha Aporia Debinta University of Indonesia
  • Riesye Arisanti
  • Andira Hardjodipuro

Keywords:

generalized pustular psoriasis, secukinumab, biologic agent, pediatric

Abstract

Currently there is a lack of standardized treatment guidelines for pediatric psoriasis treatment using biologic agents. Children are usually among special population usually excluded from clinical trials, as such lack of available reports and supporting evidences forming recommended guidelines are challenging to be published. Especially in pustular generalized pustular psoriasis, a rare form of psoriasis, recalcitrant and difficult to manage cases of pediatric psoriasis may require more options than usual usage of topical, phototherapy or systemic treatments. We present a case of a ten-year-old female diagnosed with generalized pustular psoriasis in the last four years, successfully treated with secukinumab after years of treatment to no avail.

References

Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work. J Dermatol. 2018;45:1353–6.

Posso-De Los Rios CJ, Pope E, Lara-Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics. Pediatr Dermatol. 2014;31:430–9.

Nagai M, Imai Y, Wada Y, Kusakabe M, Yamanishi K. Serum procalcitonin and presepsin levels in patients with generalized pustular psoriasis. Dis Markers. 2018;2018.

Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatology Venereol. 2021;35:938–47.

Cline A, Bartos GJ, Strowd LC, Feldman SR. Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. Children. 2019;6:103.

British Association of Dermatologists. British Association of Dermatologists Guidelines for biologic therapy for psoriasis Methods, evidence and recommendations. 2017;1–390.

Wells LE, Evans T, Hilton R, Wine Lee L, Ruth N. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis. Pediatr Dermatol. 2019;36:384–5.

Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39:42–8.

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC. J Eur Acad Dermatology Venereol. 2017;31:1951–63.

Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatolog Treat. 2022;33:2038–50.

Downloads

Published

2023-10-12

How to Cite

1.
Budianti WK, Debinta AA, Arisanti R, Hardjodipuro A. Successful treatment of secukinumab in a ten-year old with generalized pustular psoriasis recalcitrant with conventional therapy. J Pak Assoc Dermatol [Internet]. 2023Oct.12 [cited 2024May22];33(4):1681-4. Available from: https://jpad.com.pk/index.php/jpad/article/view/2321

Issue

Section

Case Reports